BACKGROUND: The availability of various oral contraceptive (OC) pill formulations with different hormone compositions suggests that there is potential to align a particular product with an individual user's needs and preferences. To explore this concept further, a survey was conducted of current users of OCs to define and confirm areas of specific needs, and to gain insight into their views and preferences for OC formulations. METHODS: During November and December 2015, women users (n=615) of OCs in five Central and Eastern European countries were surveyed in face-to-face interviews conducted by experienced interviewers. The survey questionnaire comprised 34 questions about the use of and specific needs for OCs. RESULTS: Four basic needs of women taking OCs were identified: reliable contraception, reversibility of contraception, no effect on body weight and safety. Overall, 85% of surveyed women indicated that prevention of pregnancy was the main reason for taking OCs. Weight gain was the side effect of greatest concern with OC use (46% spontaneous answer; 65% aided answer). Independent behavioural segmentation analysis identified four groups - Solved Cycle Problems (46% of participants), Low Hormone Content (22%), Lifestyle (17%) and Beauty (14%) - which characterised the women according to needs and preferences beyond the basic needs of OCs. Each group had unique features and distinct preferences for different formulations of OCs. CONCLUSIONS: Aligning product advantages with specific individual needs may enhance users' overall experience with OCs as a contraceptive option.

Carol Davila University of Medicine and Pharmacy Emergency University Hospital Bucharest Bucharest Romania

Department of Obstetrics and Gynecology 2nd Faculty of Medicine Charles University Prague Motol University Hospital Prague Czech Republic

Department of Obstetrics Gynecology and Reproductive Health Belarusian Medical Academy of Postgraduate Education Minsk Belarus

International Women's Healthcare Department Gedeon Richter Plc Budapest Hungary

Medical Division Gedeon Richter Plc Budapest Hungary

Zobrazit více v PubMed

Shoupe D, Mishell DR., Jr . Oral contraceptives. In: Shoupe D, Kjos SL, editors. Current Clinical Practice: The Handbook of Contraception: A Guide for Practical Management. Totowa, NJ: Humana Press; 2006. pp. 13–43. http://dx.doi.org/10.1007/978-1-59745-150-5. DOI

Evans G, Sutton EL. Oral contraception. Med Clin North Am. 2015;99:479–503. http://dx.doi.org/10.1016/j.mcna.2015.01.004. PubMed DOI

Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27:3–12. http://dx.doi.org/10.1016/j.beem.2012.11.004. PubMed DOI

Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014;5:201–13. http://dx.doi.org/10.1177/2042098614548857. PubMed DOI PMC

Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13–24. http://dx.doi.org/10.1016/j.beem.2012.09.004. PubMed DOI

United Nations, Department of Economic and Social Affairs, Population Division. Trends in Contraceptive Use Worldwide 2015 (ST/ESA/SER.A/349) 2015. [Last accessed: 12 December 2017]. Available at http://www.un.org/en/development/desa/population/publications/pdf/family/trendsContraceptiveUse2015Report.pdf.

Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001–2008. Am J Public Health. 2014;104(Suppl 1):S43–8. http://dx.doi.org/10.2105/AJPH.2013.301416. PubMed DOI PMC

Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41:241–50. http://dx.doi.org/10.1111/j.1728-4465.2010.00250.x. PubMed DOI

Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann. 2014;45:301–14. http://dx.doi.org/10.1111/j.1728-4465.2014.00393.x. PubMed DOI PMC

Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception. 1998;57:103–9. PubMed

Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon) Dermatology. 2001;203:38–44. http://dx.doi.org/10.1159/000051701. PubMed DOI

Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®) Clin Drug Investig. 2002;22:221–31.

Bitzer J. Belara – proven benefits in daily practice. Eur J Contracept Reprod Health Care. 2005;10(Suppl 1):19–25. http://dx.doi.org/10.1080/13625180500434962. PubMed DOI

Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76:342–7. http://dx.doi.org/10.1016/j.contraception.2007.07.002. PubMed DOI

Lello S, Primavera G, Colonna L, Vittori G, Guardianelli F, Sorge R, Raskovic D. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol. 2008;24:718–23. http://dx.doi.org/10.1080/09513590802454943. PubMed DOI

Plewig G, Cunliffe WJ, Binder N, Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80:25–33. http://dx.doi.org/10.1016/j.contraception.2009.02.016. PubMed DOI

Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Investig. 2010;30:211–20. http://dx.doi.org/10.2165/11532910-000000000-00000. PubMed DOI

Kerscher M, Reuther T, Krueger N, Buntrock H. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol. 2013;27:601–8. http://dx.doi.org/10.1111/j.1468-3083.2012.04497.x. PubMed DOI

Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501. http://dx.doi.org/10.1097/01.AOG.0000175834.77215.2e. PubMed DOI

Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–21. http://dx.doi.org/10.1097/01.AOG.0000175834.77215.2e. PubMed DOI

Rapkin AJ, Mikacich JA. Premenstrual syndrome in adolescents: diagnosis and treatment. Pediatr Endocrinol Rev. 2006;3(Suppl 1):132–7. PubMed

Hernádi L, Marr J, Trummer D, De Leo V, Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception. 2009;80:18–24. http://dx.doi.org/10.1016/j.contraception.2009.01.016. PubMed DOI

Brill K, Then A, Beisiegel U, Jene A, Wünsch C, Leidenberger F. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial. Contraception. 1996;54:291–7. PubMed

Endrikat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55:131–7. PubMed

Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014;89:242–52. http://dx.doi.org/10.1016/j.contraception.2013.12.003. PubMed DOI

Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg. Eur J Contracept Reprod Health Care. 1999;4:17–25. [No authors listed] PubMed

The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. Eur J Contracept Reprod Health Care. 1999;4:9–15. [No authors listed] PubMed

Fruzzetti F, Genazzani AR, Ricci C, De Negri F, Bersi C, Carmassi F. A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control. Contraception. 2001;63:303–7. PubMed

Endrikat JS, Milchev NP, Kapamadzija A, Georgievska J, Gerlinger C, Schmidt W, Feroze S. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009;79:428–32. http://dx.doi.org/10.1016/j.contraception.2008.12.007. PubMed DOI

Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clinical Endocrinol Metab. 1995;80:1816–21. http://dx.doi.org/10.1210/jcem.80.6.7775629. PubMed DOI

Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschmidt I, Heithecker R. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25–34. PubMed

Thorneycroft IH. Yasmin: the reason why. Eur J Contracept Reprod Health Care. 2002;7(Suppl 3):13–8. discussion 42–3. PubMed

Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet. 2009;280:255–61. http://dx.doi.org/10.1007/s00404-008-0907-x. PubMed DOI

Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, Xiao-Ping J, Jian L, Shu-Ying W, Cheng-Liang X, Zheng-Ai X, Tian-Fu Y. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig. 2010;30:387–96. http://dx.doi.org/10.2165/11318460-000000000-00000. PubMed DOI

Lindeque BG. Contraception for first-time users. SA Fam Pract. 2008;50(2):13–18.

Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025–32. http://dx.doi.org/10.1056/NEJMoa013202. PubMed DOI

Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, McDonald JA, Daling JR, Bernstein L, Malone KE, Wingo PA, Simon MS, Norman SA, Strom BL, Ursin G, Weiss LK, Burkman RT, Spirtas R. Oral contraceptive formulation and risk of breast cancer. Contraception. 2012;85:342–50. http://dx.doi.org/10.1016/j.contraception.2011.08.007. PubMed DOI PMC

Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013;18:27–43. PubMed